Letter/Comment
The latest advocacy letters and comments from the 黑料正能量 Association.
Letter to the Senate Finance Committee leadership supporting the Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018.
The 黑料正能量 Association and others support Senators Grassley and Feinstein of the Senate Judiciary Committee for their leadership and commitment to reducing out-of-control prescription drug prices and stopping anti-competitive abuses that keep drug prices high.
Read the full letter below鈥
AHA letter to Energy and Commerce Committee Subcommittee on Health鈥檚 discussion draft, titled the 鈥淧andemic and All-Hazards Preparedness Reauthorization Act of 2018.鈥
May 31, 2018
The 黑料正能量 Association responds to the House Energy and Commerce Committee鈥檚 request for information (RFI) on how best to keep medical devices secure over their useful lifetimes and, specifically, "legacy technology challenges, opportunities, considerations and suggestions鈥
AHA responds to the CMS Request for Information on direct provider contracting.
AHA responds to the Food and Drug Administration鈥檚 Medical Device Safety Action Plan, particularly with regard to advancing medical device cybersecurity.
AHA's comment on the CMS proposed rule to amend requirements that states assess their Medicaid fee-for-service provider payments to determine if they are sufficient to ensure beneficiary access to covered services.
AHA letter to Senators Alexander and Murray expressing support for the Senate Health, Education, Labor and Pensions Committee鈥檚 bipartisan reauthorization of the hospital and public health preparedness programs contained within S. 2852, the Pandemic and All-Hazards Preparedness and Advancing鈥
AHA letter to Senators Isakson and Tester expressing support for S. 2372, the VA Maintaining Internal Systems and Strengthening Integrated Outside Networks Act of 2018 (VA MISSION Act of 2018).
AHA comments to HRSA regarding proposed rule that would further delay the effective date for implementing final regulations regarding the 340B Drug Pricing Program ceiling price and drug manufacturers鈥 civil monetary penalties (CMPs) for violations of the ceiling price.